Cochrane · systematic review · CD013011
Immediate‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults
Cândido, RCF, Menezes de Padua, CA, Golder, S, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
Developmental, Psychosocial and Learning ProblemsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
9
No studies
5
Included studies
NR
No studies 5 · 35.7%Ungraded 0 · 0%Very low 8 · 57.1%Low 1 · 7.1%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Immediate‐release methylphenidate versus placebo for attention deficit hyperactivity disorder (ADHD) in adults
Population: adults with ADHD (available evidence for participants aged between 25 to 53 years old)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Efficacy (changes in symptoms of ADHD): investigator‐rated Immediate‐release methylphenidate vs placebo | no estimate extracted | 1 study · 146 participants | Very low Downgraded: risk of bias, imprecision |
Efficacy (changes in symptoms of ADHD): participant‐rated Immediate‐release methylphenidate vs placebo | no estimate extracted | 2 studies · 138 participants | Very low Downgraded: risk of bias, imprecision |
Clinical impression: severity Immediate‐release methylphenidate vs placebo | no estimate extracted | 2 studies · 139 participants | Very low Downgraded: risk of bias, imprecision |
Clinical impression: improvement Immediate‐release methylphenidate vs placebo | no estimate extracted | 1 study · 49 participants | Low Downgraded: risk of bias, imprecision |
Anxiety: investigator‐rated Immediate‐release methylphenidate vs placebo | no estimate extracted | 1 study · 19 participants | Very low Downgraded: risk of bias, imprecision |
Depression: investigator‐rated Immediate‐release methylphenidate vs placebo | no estimate extracted | 1 study · 19 participants | Very low Downgraded: risk of bias, imprecision |
Harms: adverse events (poorly assessed and reported) Immediate‐release methylphenidate vs placebo | no estimate extracted | NR | No studies |
Immediate‐release methylphenidate versus lithium for attention deficit hyperactivity disorder (ADHD) in adults
Population: adults with ADHD (available evidence for participants aged between 25 to 53 years old)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Efficacy (changes in symptoms of ADHD): investigator‐rated Immediate‐release methylphenidate vs lithium | no estimate extracted | 1 study · 46 participants | Very low Downgraded: risk of bias, imprecision |
Efficacy (changes in symptoms of ADHD): participant‐rated ‐ not reported Immediate‐release methylphenidate vs lithium | no estimate extracted | NR | No studies |
Clinical impression: severity ‐ not reported Immediate‐release methylphenidate vs lithium | no estimate extracted | NR | No studies |
Clinical impression: improvement‐ not reported Immediate‐release methylphenidate vs lithium | no estimate extracted | NR | No studies |
Anxiety: investigator‐rated Immediate‐release methylphenidate vs lithium | no estimate extracted | 1 study · 46 participants | Very low Downgraded: risk of bias, imprecision |
Depression: investigator‐rated Immediate‐release methylphenidate vs lithium | no estimate extracted | 1 study · 46 participants | Very low Downgraded: risk of bias, imprecision |
Harms: adverse events (poorly assessed and reported) Immediate‐release methylphenidate vs lithium | no estimate extracted | NR | No studies |